Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
MEMOPTIC in Chronic Open-angle Glaucoma
NCT04499157Terminated
- Sponsor
- CHU Amiens-Picardie
- Start
- Sep 2020
- Primary completion
- Jan 2024
- Countries
- 1
01
Overview
Trial of MEMOPTIC in open-angle glaucoma (OAG) (2 arms), sponsored by CHU Amiens-Picardie. Primary endpoint: Variation of visual field at 2 years. Started Sep 2020; status: terminated.
02
Drugs
MEMOPTIC
03
Conditions
open-angle glaucoma (OAG)
Beyond the preview
Go deeper on NCT04499157.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT04499157.